Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID

NCT02963064 is registered in ClinicalTrials.gov with Jasper Therapeutics, Inc. as lead sponsor.

NCT NCT02963064
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02963064 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID
Lead sponsor
Jasper Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
March 20, 2017
Completion date
July 7, 2025
Enrollment
23 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

scid